Literature DB >> 23482795

Statistical identification of predictors for paclitaxel-induced peripheral neuropathy in patients with breast or gynaecological cancer.

Yuko Kanbayashi1, Toyoshi Hosokawa, Jo Kitawaki, Tetsuya Taguchi.   

Abstract

AIM: The aim of this study was to identify predictors for paclitaxel-induced peripheral neuropathy (PIPN). PATIENTS AND METHODS: We conducted a retrospective analysis of 227 patients who had been treated with paclitaxel at a single institution between January 2008 and July 2011. At the time of chemotherapy completion, the severity of PIPN was graded on a scale of 0-5, in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events v4.0. Multivariate-ordered logistic regression analysis was employed to examine the relationship between various predictive factors and the occurrence of PIPN.
RESULTS: Diabetes mellitus [odds ratio (OR)=0.070], age (OR=1.991), co-administration of neurotropin (OR=3.654), co-administration of opioids (OR=0.312), co-administration of vitamin B12 (OR=2.554), co-administration of antidepressant (OR=4.754) and co-administration of gabapentinoids (OR=14.620), were significantly associated with reduction of or less serious PIPN.
CONCLUSION: Our study indicates that PIPN may be alleviated by co-administration of opioids.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23482795

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials.

Authors:  Dawn L Hershman; Cathee Till; Jason D Wright; Danielle Awad; Scott D Ramsey; William E Barlow; Lori M Minasian; Joseph Unger
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

2.  Concomitant Medications and Risk of Chemotherapy-Induced Peripheral Neuropathy.

Authors:  Lara Sánchez-Barroso; Maria Apellaniz-Ruiz; Gerardo Gutiérrez-Gutiérrez; María Santos; Juan M Roldán-Romero; Maria Curras; Laura Remacha; Bruna Calsina; Isabel Calvo; María Sereno; María Merino; Jesús García-Donas; Beatriz Castelo; Eva Guerra; Rocio Letón; Cristina Montero-Conde; Alberto Cascón; Lucía Inglada-Pérez; Mercedes Robledo; Cristina Rodríguez-Antona
Journal:  Oncologist       Date:  2018-11-23

3.  Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy.

Authors:  Yuko Kanbayashi; Megumi Inagaki; Hiroshi Ueno; Toyoshi Hosokawa
Journal:  Med Oncol       Date:  2017-07-07       Impact factor: 3.064

4.  Comparison of the efficacy of cryotherapy and compression therapy for preventing nanoparticle albumin-bound paclitaxel-induced peripheral neuropathy: A prospective self-controlled trial.

Authors:  Yuko Kanbayashi; Koichi Sakaguchi; Takeshi Ishikawa; Yoshimi Ouchi; Katsuhiko Nakatsukasa; Yusuke Tabuchi; Fuminao Kanehisa; Minako Hiramatsu; Ryo Takagi; Isao Yokota; Norito Katoh; Tetsuya Taguchi
Journal:  Breast       Date:  2019-12-20       Impact factor: 4.380

5.  Risk factors for paclitaxel-induced peripheral neuropathy in patients with breast cancer.

Authors:  Zohreh Ghoreishi; Seyedali Keshavarz; Mohammad Asghari Jafarabadi; Zahra Fathifar; Karyn A Goodman; Ali Esfahani
Journal:  BMC Cancer       Date:  2018-10-05       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.